Caxton Associates (New York)’s Acceleron Pharma XLRN Stock Holding History

Caxton Associates (New York)’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,924	Closed	-$331K	–	705
2021 Q3	$331K	Buy	+1,924	New	+$252K	0.04%	297

Caxton Associates (New York)'s XLRN Position: Q4 2021 in Review

Caxton Associates (New York) sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 1,924 shares — an estimated $331K sold.

Caxton Associates (New York) first reported a position in XLRN in Q3 2021 and held it in 1 quarter. The position peaked at $331K in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Caxton Associates (New York) reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Caxton Associates (New York) sold 1,924 Acceleron Pharma shares in Q4 2021, an estimated $331K.
Caxton Associates (New York) first reported a position in Acceleron Pharma in Q3 2021 and held it in 1 quarter.
Caxton Associates (New York)'s Acceleron Pharma position peaked at $331K in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Caxton Associates (New York)'s 13F filing for Q4 2021, filed 14 Feb 2022.